Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

Phase 2

Completed

• Conditions: Diabetic Foot Ulcers

• Registration Number: NCT01291160
• Lead Sponsor: Neogenix, LLC dba Ogenix

Brief Summary

This is a multicenter, prospective, parallel, double-blinded, validation study of up to 12 weeks duration to evaluate the safety and effectiveness of EPIFLO for the treatment of Diabetic Foot Ulcer. The primary objectives of this study are: 1) to evaluate the effectiveness of EPIFLO in combination with standard wound therapy on wound healing as compared to standard wound therapy alone; and 2) Screening for potential safety issues.

Diabetic subjects with a Diabetic Foot Ulcer present for a minimum of 30 days will be enrolled. All subjects enrolled in the study will receive a standard wound therapy regimen consisting of, wound cleansing, moist wound care, off-loading and as appropriate, aggressive debridement. Subjects will be randomized to either the Treatment arm or the Control arm. Subjects will be assessed weekly for signs of wound healing during the 12-week Treatment Period, once two weeks after wound closure and once at the end of 12-week durability Period.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Study First Submitted: 2011-02-04
• Study First Submitted QC: 2011-02-07
• Study First Posted: 2011-02-08
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Status Verified: 2014-04
• Results First Submitted: 2014-04-11
• Results First Submitted QC: 2014-04-11
• Last Update Submitted: 2014-04-11
• Results First Posted: 2014-05-13
• Last Update Posted: 2014-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Male and female patients 20-90 years of age with type 1 or type 2 diabetes mellitus with non-healing, full-thickness, University of Texas Classification of Diabetic Foot Ulcers Class IA diabetic foot ulcers of at least 4 weeks duration, but not greater than 52 weeks, measuring 1 -10 cm2 in area (Area = length x width) 50% at least from 65+ age group
• Any diabetic foot ulcer at or below the malleoli
• Patients with partial amputation up to & including a TMA
• Subjects; between 20-90 years of age with a diabetic foot ulcer; 50% at least from 65+ age group
• Subjects must have had the wound open for at least 4 weeks from day one on screening visit.
• Subjects wound must be ≥1 cm2 in size at screening visit, but not greater than 10 cm2.
• Subject's ABI should be ≥ 0.7 on the study limb or transcutaneous partial pressure oxygen (TcpO2) >40mmHg; or a toe pressure ≥40mmHg; or a Doppler waveform consistent with adequate flow in the foot(biphasic or triphasic waveforms) at screening
• No active malignancy except non-melanoma skin cancer
• Subject and/or caregiver must be willing and able to learn and perform the duties of dressing changes, and demonstrate the ability to do so.
• If patient has had a history of alcohol or substance abuse within 6 months prior to base line period, should provide proof of treatment.

Exclusion Criteria

• Wounds of duration >52 weeks
• Evidence of gangrene on any part of affected limb;
• Subjects with active Charcot's foot on the study limb;
• Subjects scheduled to undergo vascular surgery, angioplasty or thrombolysis;
• Subjects with infected target ulcers, accompanied by cellulitis, known or suspected osteomyelitis, or other clinical evidence of infection;
• Index ulcer has exposed tendons, ligaments, muscle, or bone.
• ulcers present in between toes
• Target limb is infected at beginning of study
• Must never have had malignancy on study limb
• Oral, or IV antibiotic/antimicrobial agents or medications have been used within 2 days (48 hours) of baseline.
• Patients with steroids >7mg dosage are excluded
• Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening date.
• Subject may not be pregnant at the time of treatment.
• Subjects with ulcer that has a total Surface Area of greater than 10 cm2 at Screening Visit as measured by a member of the study staff;
• Subject is undergoing renal dialysis, has known immune insufficiency, other than Diabetes Mellitus
• Ulcers which decrease in area by >30% during the screening 1-week run-in period
• History of peripheral vascular repair within the 30 days of baseline.
• Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
• No known "patient-reported" alcohol or substance abuse within three months prior to baseline.
• Subject currently enrolled or participated within 30 days of baseline in another investigational device, drug or biological trial.
• Subject allergic to a broad spectrum of primary & secondary dressing materials,including occlusive dressings and the adhesives on such dressings.
• Subject with Chopart amputation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of 100% Wound Closure	before or at week 12

Trial Locations

Locations (11)

Carl T. Hayden VA Medical Center; 🇺🇸 Phoenix, Arizona, United States

Southern AZ VA Health Care System; 🇺🇸 Tucson, Arizona, United States

Dean Vayser, DPM; 🇺🇸 Encinitas, California, United States

California School of Podiatric Medicine; 🇺🇸 Fresno, California, United States

The Diabetic Foot; 🇺🇸 San Marcos,, California, United States

UF College of Medicine-Jacksonville; 🇺🇸 Jacksonville, Florida, United States

Bruce W. Carter Dept. of Veterans Affairs Medical Center, Miami VA Health Care System; 🇺🇸 Miami, Florida, United States

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States

Ocean County Foot & Ankle Surgical Associates; 🇺🇸 Toms River,, New Jersey, United States

Ohio College of Podiatric Medicine; 🇺🇸 Independence, Ohio, United States

Scroll for more (1 remaining)